Novavax’s COVID-19 Vaccine Boost From First Phase I Data

A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.    

COVID-19 SARS,Coronaviridae , SARS-CoV, SARSCoV, virus 2020 , MERS-CoV ,chinese virus 2019-nCoV
• Source: Shutterstock

Novavax, Inc.’s recombinant COVID-19 vaccine candidate NVXCoV2373, given with its Matrix-M adjuvant, elicited robust antibody responses numerically better than those seen in human convalescent sera, and was generally well-tolerated, the first data from its Phase I/II study show.

The results come from the Phase I portion of the trial which evaluated two doses of the vaccine administered at...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip